Opportunity Information: Apply for RFA AI 12 048
Apply for RFA AI 12 048
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Immune Mechanisms of Virus Control (U19)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Dec 12, 2012 and posted on Dec 12, 2012.
- Applicants must submit their applications by Apr 16, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $15,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,500,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses State governments Special district governments Independent school districts Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education County governments City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Immune Mechanisms of Virus Control (IMVC) program (Funding Opportunity Number RFA-AI-12-048) is a National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) grant opportunity designed to support coordinated, multi-project research teams that work together to answer fundamental questions about how the immune system controls viral infections and how vaccines generate protection. It uses the U19 cooperative agreement mechanism, which means awardees are expected to function as part of a broader, NIH-involved research network where coordination, collaboration, and shared scientific direction are central features rather than add-ons. The program is built around the idea that complex immunology problems, especially those involving virus control, often require multiple complementary projects operating in a tightly integrated way.
At the scientific level, the opportunity focuses on identifying and defining the key molecular and cellular immune mechanisms that matter most in three main areas: first, the natural control of viral infection (why some hosts control infection better than others and what immune processes make that possible); second, the induction of protective immunity through vaccination (which immune responses are truly protective, how they are generated, and what determines their quality and durability); and third, immune-mediated pathology that can occur after infection or vaccination (situations where immune responses contribute to disease severity or adverse outcomes). The program is particularly interested in research that clarifies which immunological parameters are most important, implying an emphasis on mechanistic insight and on immune features that can be measured, compared, and ultimately used to guide vaccine or therapeutic development.
A defining feature of the IMVC program is the encouragement of studies involving multiple viruses. By comparing immune responses across different viral systems, the program aims to promote discovery of novel immune mechanisms and, importantly, generalizable principles of antiviral immunity that extend beyond any single pathogen. The viruses of interest are tied to NIAID's Emerging and Re-emerging Infectious Diseases list, signaling that the program is aligned with pathogens of public health concern and is intended to strengthen basic immunology knowledge that can be leveraged as new viral threats emerge. While the FOA points to that list rather than enumerating viruses in the text provided, the intent is clear: applications should be relevant to viruses prioritized by NIAID for emerging and re-emerging risk.
The ultimate goal is explicitly translational in its long-term impact, even though the research emphasis is basic mechanism: discovering new immune pathways and control strategies that can become targets or conceptual blueprints for future vaccines and therapeutics. In practice, this means the program is looking for work that does more than describe immune correlates; it seeks to explain causality and mechanism in ways that could plausibly inform intervention design, such as pinpointing immune cell subsets, signaling pathways, antigen presentation features, or regulatory processes that can be manipulated to improve protection or reduce harmful inflammation.
Administratively, this is a discretionary funding opportunity offered as a cooperative agreement under health-related research activity categories, and it is associated with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). The opportunity did not require cost sharing or matching. The estimated total funding amount listed is $15,000,000, with an award ceiling of $1,500,000, indicating support for multiple substantial awards while still expecting teams to define coherent, integrated scopes that fit within the ceiling.
Eligibility is broad and includes a wide range of U.S. organizations, such as public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations (including small businesses), and many governmental entities (state, county, city/township, special district governments, independent school districts, tribal governments, and public housing authorities/Indian housing authorities). The eligibility language also explicitly includes a variety of institution types and community-focused organizations, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based and community-based organizations where relevant. Foreign participation is allowed: non-U.S. entities and foreign institutions may apply, non-U.S. components of U.S. organizations are eligible, and foreign components as defined by NIH policy are permitted, reflecting NIAID's interest in leveraging global expertise and, when needed, conducting research in locations relevant to specific viral threats.
Key dates in the source data show the FOA was posted on December 12, 2012, with an original and current closing date of April 16, 2013, and an archive date of May 17, 2013, meaning the specific announcement is historical but still useful as a model for how NIAID structures multi-project networked immunology programs. The full announcement and details were provided through the NIH Grants Guide link, and the contact provided for access or linking issues was the NIH Office of Extramural Research (OER) webmaster.
Frequently Asked Questions (FAQs): Immune Mechanisms of Virus Control (IMVC) Program (RFA-AI-12-048)
What is the Immune Mechanisms of Virus Control (IMVC) program?
The IMVC program is a National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) grant opportunity intended to support coordinated, multi-project research teams studying how the immune system controls viral infections and how vaccines generate protection.
What is the Funding Opportunity Number for this program?
The Funding Opportunity Number (FOA number) is RFA-AI-12-048.
Which NIH institute is sponsoring this opportunity?
This opportunity is sponsored by NIAID (National Institute of Allergy and Infectious Diseases), which is part of NIH (the National Institutes of Health).
What award mechanism does IMVC use?
The IMVC program uses the U19 cooperative agreement mechanism.
What does it mean that this is a U19 cooperative agreement?
A U19 cooperative agreement indicates that awardees are expected to participate in an NIH-involved research network. Coordination, collaboration, and shared scientific direction are central program features, and teams are expected to operate in a coordinated, multi-project format rather than as standalone projects.
What kind of team structure is this program designed to support?
The program is designed to support coordinated, multi-project research teams that work together in a tightly integrated way to address complex immunology questions related to virus control.
What scientific areas does the IMVC program focus on?
The program emphasizes identifying and defining key molecular and cellular immune mechanisms in three main areas: (1) natural control of viral infection, (2) induction of protective immunity through vaccination, and (3) immune-mediated pathology after infection or vaccination.
What does the program mean by “natural control” of viral infection?
Natural control refers to understanding why some hosts control viral infection better than others and identifying the immune processes that enable that control.
What vaccine-related questions does IMVC aim to address?
The opportunity highlights research aimed at determining which immune responses are truly protective, how those protective responses are generated, and what factors shape their quality and durability.
Does the program include research on harmful immune responses?
Yes. One of the three primary focus areas is immune-mediated pathology, including situations where immune responses contribute to disease severity or adverse outcomes after infection or vaccination.
Is the program more interested in describing immune correlates or in explaining mechanisms?
Based on the description provided, the program prioritizes mechanistic insight and causality. It aims to clarify which immunological parameters matter most, with an emphasis on defining key molecular and cellular mechanisms.
Does IMVC encourage studies involving more than one virus?
Yes. A defining feature of IMVC is the encouragement of studies involving multiple viruses, using comparisons across viral systems to discover novel immune mechanisms and generalizable principles of antiviral immunity.
What viruses are considered relevant to this opportunity?
The viruses of interest are tied to NIAID’s Emerging and Re-emerging Infectious Diseases list. The information provided does not enumerate specific viruses, but it indicates applications should be relevant to viruses prioritized by NIAID for emerging and re-emerging risk.
What is the long-term goal of the IMVC program?
The long-term goal is to discover immune pathways and control strategies that could inform future vaccines and therapeutics, even though the research emphasis is on basic immune mechanisms.
How does the program connect basic research to translational impact?
The program seeks mechanistic explanations that could plausibly inform intervention design, such as identifying immune cell subsets, signaling pathways, antigen presentation features, or regulatory processes that could be manipulated to improve protection or reduce harmful inflammation.
Is cost sharing or matching required?
No. The opportunity did not require cost sharing or matching.
What is the estimated total funding amount for this opportunity?
The estimated total funding amount listed is $15,000,000.
What is the award ceiling?
The award ceiling is $1,500,000.
What do the listed funding levels suggest about the number and size of awards?
The estimated total funding amount and the per-award ceiling suggest support for multiple substantial awards, with teams expected to propose coherent, integrated scopes that fit within the ceiling.
What CFDA numbers are associated with this opportunity?
This opportunity is associated with CFDA 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
Who is eligible to apply?
Eligibility is broad and includes many U.S. organization types, including public and private institutions of higher education; nonprofit organizations (with and without 501(c)(3) status); for-profit organizations (including small businesses); and multiple government entity types (state, county, city/township, special district, independent school districts, tribal governments, and public housing authorities/Indian housing authorities).
Are minority-serving institutions and community-focused organizations included in eligibility?
Yes. The eligibility language explicitly includes institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based and community-based organizations where relevant.
Are foreign organizations allowed to apply?
Yes. Non-U.S. entities and foreign institutions may apply. Non-U.S. components of U.S. organizations are eligible, and foreign components (as defined by NIH policy) are permitted.
What does the allowance of foreign participation indicate about program needs?
It reflects interest in leveraging global expertise and, when needed, conducting research in locations relevant to specific viral threats.
When was this FOA posted and when did it close?
The FOA was posted on December 12, 2012. The original and current closing date listed is April 16, 2013.
Is this funding opportunity still active?
The source data indicates an archive date of May 17, 2013, meaning the specific announcement is historical (archived).
Where were the full announcement and details provided?
The full announcement and details were provided through the NIH Grants Guide link (as referenced in the information provided).
Who was listed as a contact for access or linking issues?
The contact listed for access or linking issues was the NIH Office of Extramural Research (OER) webmaster.
What type of activity category is this opportunity associated with?
It is described as a discretionary funding opportunity offered as a cooperative agreement under health-related research activity categories.
Browse more opportunities from the same category: Health
Next opportunity: Cooperative Ecosystem Studies Unit, South Florida Caribbean CESU Program
Previous opportunity: Support to Vulnerable Households (SVH) for Accelerated Rrevenue Earnings
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 12 048
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 12 048) also looked into and applied for these:
| Funding Opportunity |
|---|
| Collaborative Activities to Promote Metabolomics Research (Admin Supp) Apply for PA 13 041 Funding Number: PA 13 041 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| USAID/Cambodia Annual Program Statement (APS) for MATERNALCHILD HEALTH, TUBERCULOSIS, HIV/AIDS, AND Malaria Apply for APS 442 13 000001 Funding Number: APS 442 13 000001 Agency: Cambodia USAID Phnom Penh Category: Health Funding Amount: $100,000 |
| Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19) Apply for PA 13 042 Funding Number: PA 13 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| International Traumatic Brain Injury Research Initiative NIH Cooperative Program for Comparative Effectiveness of Clinical Tools and Therapies (U01) Apply for RFA NS 13 008 Funding Number: RFA NS 13 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanisms of HIV Related Lung Disease (U01) Apply for RFA HL 13 026 Funding Number: RFA HL 13 026 Agency: National Institutes of Health Category: Health Funding Amount: $440,000 |
| Mechanisms of HIV Related Lung Disease Data Coordinating Center (DCC) (U01) Apply for RFA HL 13 028 Funding Number: RFA HL 13 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Small Research Grants for Data Analysis and Statistical Methodology Applied to Genome wide Data (R03) Apply for PAR 13 044 Funding Number: PAR 13 044 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening Surveillance for Japanese Encephalitis in India Apply for RFA GH 13 004 Funding Number: RFA GH 13 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| AHRQ Health Services Research Projects (R01) Apply for PA 13 045 Funding Number: PA 13 045 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $250,000 |
| AHRQ Health Services Research Demonstration and Dissemination Grants (R18) Apply for PA 13 046 Funding Number: PA 13 046 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $250,000 |
| Detecting etiologies of emerging infectious diseases at the regional level Western Ghat Region of Karnataka and Kerala, India Apply for RFA GH 13 003 Funding Number: RFA GH 13 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| NIH Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (P30) Apply for RFA OD 12 007 Funding Number: RFA OD 12 007 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Strengthening Disease Prevention Research Capacity for Public Health Action in Guatemala and the Central American Region Apply for RFA GH 13 001 Funding Number: RFA GH 13 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $20,000,000 |
| Monitoring and Evaluation of Malaria Control and Elimination Activities Apply for RFA GH 13 005 Funding Number: RFA GH 13 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Prevalence and Incidence of Inflammatory Bowel Disease Apply for RFA DP 13 001 Funding Number: RFA DP 13 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $550,000 |
| NIDCD Small Grant Program (R03) Apply for PAR 13 057 Funding Number: PAR 13 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Estimating the Costs of Supporting Primary Care Practice Transformation (R03) Apply for RFA HS 13 003 Funding Number: RFA HS 13 003 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $100,000 |
| Strengthening Public Health and the Public Health Laboratory System of Cambodia under the Presidents Emergency Plan for AIDS Relief Program under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1305 Funding Number: CDC RFA GH13 1305 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $350,000 |
| HIT Capacity Building Initiative for Ryan White HIV/AIDS Program AIDS Drug Assistance Program (ADAP) Grantees Apply for HRSA 13 152 Funding Number: HRSA 13 152 Agency: Health Resources and Services Administration Category: Health Funding Amount: $100,000 |
| R40 MCH Autism Intervention Research Apply for HRSA 13 195 Funding Number: HRSA 13 195 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 12 048", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.